{"name":"Celtaxsys, Inc.","slug":"celtaxsys-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CTX-4430","genericName":"CTX-4430","slug":"ctx-4430","indication":"Chronic Granulomatous Disease","status":"phase_2"}]}],"pipeline":[{"name":"CTX-4430","genericName":"CTX-4430","slug":"ctx-4430","phase":"phase_2","mechanism":"CTX-4430 is a small molecule inhibitor of the NADPH oxidase 2 (NOX2) enzyme.","indications":["Chronic Granulomatous Disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNX0ZIZllHVHlUQ1RmUXpGX0FIYWVHS3hYSjlxczctaEhTbDBLS2VaUUVTOE8yeHBmMmVtaGVZenVqZWdKSlVWcHU0cFB2b2EtWTdzMXp6VmI3WmVXcXRWenQxVGlmTlpfRFZyU2pfZlNOcFdFLWluTWN3WEZOOUJmMjFXdEFkQVFqdjRHclZVQ2l0Wm5aVUx4RVFnQXF1S0xnb0N3?oc=5","date":"2025-10-06","type":"deal","source":"The Business Journals","summary":"Atlanta biotech firm signs licensing deal aimed at treating cancer pain - The Business Journals","headline":"Atlanta biotech firm signs licensing deal aimed at treating cancer pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQZnJDSWwxM2hmWFpfZjBCUW5jdFBhenpGRnd2Wi1WT001czduZ0k5UktoVVFjQVh5QWR6NUJ3UnRwTGEyYUVUd29MWFRMQXVlYkNLTDUya29DUW56dWpldkotZUVTWHJMRF90S3RFVDNZazhTeGFNU0dXNEhBNWJXX0NjU1BaNnVxUDl2cmNiZVpBb1VoaGVldlVweFlSLVl4S1RrdkdEaXlKOXVyN2l4a0xCSQ?oc=5","date":"2024-07-18","type":"trial","source":"Clinical Leader","summary":"3 Reasons Optimized Trials Are Ideal For Pulmonary And Respiratory Research - Clinical Leader","headline":"3 Reasons Optimized Trials Are Ideal For Pulmonary And Respiratory Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPazRaU2puQTFYUUNRcEN0S3E3c281OVBSOTZiS2VsTk9EYXA2V0xHMlpsZENBOFpYQm9qQm9ISkY3akNQVmMyYlVabjhrTnJaMjhhaXI2ZzJMOXB1RkpCUHBuN3hMTHpyZklUajJnVV9fZ1lhWmhVUGdIckJWckNNTTJsUEN1aVkxYXpLSGxLRkZzVXc1WU5rSDEtLTJtVC00RF9JdGl4cXotdVBvMzFwanlxdmNOTWxCOWVpVUk4UWNBZ2QtWW1hNWhYLUJ3cUczWDJWNGlfM2RUSHdlYzZNYjc4SHMzVXhS?oc=5","date":"2023-11-10","type":"pipeline","source":"respiratory-therapy.com","summary":"Celtaxsys Cystic Fibrosis Drug Granted Orphan Designation - respiratory-therapy.com","headline":"Celtaxsys Cystic Fibrosis Drug Granted Orphan Designation - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQUjd5ZFBLS0d2dl9maHZmbG9odURvMWQzdDZyRjVDLVdEbUJuY2lWd3ZZbWZHQjZadk50aFRSYW9RYjVTQkxzLVQtc09BdkdjTlRTSHY1ZHlvZmQwcWZub2x4cUlPOHJJaGV6cjZuaERWMDBmaEFWbE9OenQ3UjhuR1NMVUZOdzFyT2dJVG1tRTNhaWc?oc=5","date":"2018-08-02","type":"pipeline","source":"BioPharma Dive","summary":"Celtaxsys CF drug misses mark on lung function - BioPharma Dive","headline":"Celtaxsys CF drug misses mark on lung function","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOU2t0VVd2YURkcjdGYm0zMmpQeVZWLU9jU1VoVjgxOXlIVVNUR0NuQ1Q3ZUdJbk9hMGVFQWI0cmhubk9MZklfdkNiQ2Fwclhqd2FWRVEzRldNakx0ak5LOTRpWksyT01EQnZURUt0WEFRQmJFTEtUVjZVTUU5elNrNkdYY1hzLTVCRlpnWmNRUkFkbzVIRC16RUR0MjVYQ25QeE9qS29aekk4MENURkE?oc=5","date":"2018-08-02","type":"trial","source":"Fierce Biotech","summary":"Celtaxsys’ cystic fibrosis drug reduces lung exacerbations in phase 2 study - Fierce Biotech","headline":"Celtaxsys’ cystic fibrosis drug reduces lung exacerbations in phase 2 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNaGxxNkRKTG9uYmF2Rzg5MTRRVmI4d3prU2pCYmtsWXU1SDBMSkFXdE1FZWhpeFBDNjc4ZjFoM2JXYlpZVHZKb1pBZGdPODREVzZxMHJmX2I0MDR4cHFMV3NrQWwtLXoyUmM3cWdSckJkWHBDWldUaTMydW1RQmJfeFpkUE80d3FwaWgyYmx5VUZ4ZHJwNjB3RGZVcFRPOGo3dkRZZkhta0phTEJmNnVXQzZnbTd6N193cXRtUWRibw?oc=5","date":"2018-07-19","type":"trial","source":"Clinical Leader","summary":"A Cost-Utility Analysis Of Vertex's CF Drugs — What It Teaches Us About Trial Design - Clinical Leader","headline":"A Cost-Utility Analysis Of Vertex's CF Drugs — What It Teaches Us About Trial Design","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}